Magazine Article | July 3, 2023

Companies To Watch: Kinaset Therapeutics

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Moving fast in the respiratory space to advance a potential first-time therapy.

Kinaset Therapeutics is developing its single asset, an inhaled pan-JAK (Janus kinase signal transducer) inhibitor, initially for severe asthma and other respiratory diseases such as chronic obstructive pulmonary disease (COPD). Coded KN-002, the acquired pipeline product has entered a U.K.-based Phase 1b trial to assess safety and optimum dosing in patients with asthma treated with standard-of-care and patients with COPD receiving standard-of-care inhaled medicines. Further in-licensing may also expand the pipeline.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader